Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new chemical drugs: Tranexamic Acid and Sodium Chloride Injection, and Levocarnitine Oral Solution. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by addressing bleeding disorders and carnitine deficiency.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in creating medical solutions for various health conditions, with a market focus on drug production and registration in China.
Average Trading Volume: 11,720,126
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.79B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.